Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female adults \>/= 60 to \</=64 years of age (from the 60th birthday up to, but not including, the 65th birthday) at enrollment.~2. Healthy adults, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy or requiring hospitalization within 3 months before receipt of investigational product, as determined by medical history, physical examination, laboratory screening, and clinical judgment of the investigator.~3. Female subjects who are not of childbearing potential.~Exclusion Criteria:~1. Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.~2. History of microbiologically proven invasive disease caused by S pneumoniae.~3. Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Multivalent (Type: EXPERIMENTAL): Pneumococcal conjugate vaccine
- Control (Type: ACTIVE_COMPARATOR): Prevnar 13 and PPSV23

Based on this trial design, predict the completion outcome and termination type (if applicable).